Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
Portfolio Pulse from Lara Goldstein
The article discusses recent developments in the field of psychedelic therapies for mental health disorders. Small Pharma's (OTC:DMTTF) Phase 1b study on DMT and SSRIs for major depressive disorder (MDD) has released new findings. TheraPsil, a Canadian non-profit, has launched an MDMA-assisted psychotherapy training program. Apex Labs' psilocybin macrodose drug protocol has been approved for a Canadian veteran's treatment-resistant depression. The AdvisorShares Psychedelics ETF (NYSE:PSIL) has been on a slow downtrend. Other companies mentioned include GH Research (NASDAQ:GHRS), COMPASS Pathways (NASDAQ:CMPS), Mind Medicine (NASDAQ:MNMD), Enveric Biosciences (NASDAQ:ENVB), Bright Minds Biosciences (NASDAQ:DRUG), Silo Pharma (NASDAQ:SILO), Atai Life Sciences (NASDAQ:ATAI), FSD Pharma (NASDAQ:HUGE), Incannex Healthcare (NASDAQ:IXHL), Lucy Scientific Discovery (NASDAQ:LSDI), and Cybin Inc. (NYSE:CYBN).
October 02, 2023 | 1:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Small Pharma's Phase 1b study on DMT and SSRIs for MDD has released promising results.
The positive results from the Phase 1b study could potentially boost investor confidence in Small Pharma, leading to a short-term increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
The AdvisorShares Psychedelics ETF (PSIL) has been on a slow downtrend.
The consistent downtrend in the ETF's price could potentially discourage investors, leading to a short-term decrease in its stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100